Esperion Therapeutics (ESPR) said Wednesday it has completed a series of financing agreements to repay a part of its current $265 million convertible debt facility.
The company said it obtained a $150 million senior term loan led by funds managed by Athyrium Capital Management and joined by funds managed by HealthCare Royalty. Esperion added that it also issued new $100 million convertible notes to accredited investors.
The new notes will mature on June 15, 2030, and will bear a semiannual interest payment, the company said.
Esperion said it intends to use the loan proceeds and roughly $60 million of the proceeds from the new notes to repay $210 million of the current convertible debt, while the remaining $40 million of the proceeds would be allocated as operating cash.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。